Structure-based design of a selective heparanase inhibitor as an antimetastatic agent

Molecular Cancer Therapeutics

Volumn 3, Issue 9, 2004, Pages 1069-1077

  Ishida, Keisuke ^a,b   Hirai, Go ^c   Murakami, Koji ^b   Teruya, Takayuki ^a,d   Simizu, Siro ^a   Sodeoka, Mikiko ^c   Osada, Hiroyuki ^a,d  

^a Japan Science and Technology Agency   (Japan)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

^c TOHOKU UNIVERSITY   (Japan)

^d SAITAMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 HEXADECANOYL 5 HYDROXYMETHYLTETRONIC ACID; ANTIMETASTATIC AGENT; ANTINEOPLASTIC AGENT; DIAZOMETHANE; ENZYME INHIBITOR; HEPARANASE; RK 682; UNCLASSIFIED DRUG;

ALKYLATION; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BENZYLATION; CANCER CELL CULTURE; CANCER INVASION; CELL MIGRATION; CONTROLLED STUDY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; FIBROSARCOMA; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; CELL MOVEMENT; DRUG DESIGN; GLUCURONIDASE; HUMANS; LIGANDS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PHOSPHOPROTEIN PHOSPHATASE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 4143140258     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Bame KJ. Heparanases: endoglycosidases that degrade heparan sulfate proteoglycans. Glycobiology 2001;11:91-8R.
2. Parish CR, Freeman C, Hulett MD. Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta 2001;1471:M99-108.
3. Fairbanks MB, Mildner AM, Leone JW, et al. Processing of the human heparanase precursor and evidence that the active enzyme is a heterodimer. J Biol Chem 1999;274:29587-90.
4. Toyoshima M, Nakajima M. Human heparanase. Purification, characterization, cloning, and expression. J Biol Chem 1999;274:24153-60.
5. Vlodavsky I, Friedmann Y, Elkin M, et al. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med 1999;5:793-802.
6. Hulett MD, Freeman C, Hamdorf BJ, Baker RT, Harris MJ, Parish CR. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat Med 1999;5:803-9.
7. Kussie PH, Hulmes JD, Ludwig DL, et al. Cloning and functional expression of a human heparanase gene. Biochem Biophys Res Commun 1999; 261:183-7.
8. Dempsey LA, Brunn GJ, Platt JL. Heparanase, a potential regulator of cell-matrix interactions. Trends Biochem Sci 2000;25:349-51.
9. Vlodavsky I, Eldor A, Haimovitz-Friedman A, et al. Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. Invasion Metastasis 1992;12:112-27.
10. Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 2001; 108:341-7.
11. Nakajima M, Irimura T, Nicolson GL. Heparanases and tumor metastasis. J Cell Biochem 1988;36:157-67.
12. Simizu S, Ishida K, Wierzba MK, Sato TA, Osada H. Expression of heparanase in human tumor cell lines and human head and neck tumors. Cancer Lett 2003;193:83-9.
13. Nakajima M, Irimura T, Di Ferrante D, Di Ferrante N, Nicolson GL. Heparan sulfate degradation: relation to tumor invasive and metastatic properties of mouse B16 melanoma sublines. Science 1983;220:611-3.
14. Vlodavsky I, Mohsen M, Lider O, et al. Inhibition of tumor metastasis by heparanase inhibiting species of heparin. Invasion Metastasis 1994;14: 290-302.
15. Parish CR, Freeman C, Brown KJ, Francis DJ, Cowden WB. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res 1999;59:3433-41.
16. Gohji K, Hirano H, Okamoto M, et al. Expression of three extracellular matrix degradative enzymes in bladder cancer. Int J Cancer 2001;95: 295-301.
17. Koliopanos A, Friess H, Kleeff J, et al. Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res 2001;61:4655-9.
18. Elkin M, Ilan N, Ishai-Michaeli R, et al. Heparanase as mediator of angiogenesis: mode of action. FASEB J 2001;15:1661-3.
19. Goldshmidt O, Zcharia E, Abramovitch R, et al. Cell surface expression and secretion of heparanase markedly promote tumor angiogenesis and metastasis. Proc Natl Acad Sci U S A 2002;99:10031-6.
20. Nugent MA, Iozzo RV. Fibroblast growth factor-2. Int J Biochem Cell Biol 2000;32:115-20.
21. Irimura T, Nakajima M, Nicolson GL. Chemically modified heparins as inhibitors of heparan sulfate specific endo-β -glucuronidase (heparanase) of metastatic melanoma cells. Biochemistry 1986;25:5322-8.
22. Bar-Ner M, Eldor A, Wasserman L, et al. Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin species. Blood 1987;70:551-7.
23. Saiki I, Murata J, Nakajima M, Tokura S, Azuma I. Inhibition by sulfated chitin derivatives of invasion through extracellular matrix and enzymatic degradation by metastatic melanoma cells. Cancer Res 1990;50:3631-7.
24. Ishida K, Teruya T, Simizu S, Osada H. Exploitation of heparanase inhibitors from microbial metabolites using an efficient visual screening system. J Antibiot 2004;57:136-42.
25. 1 phase. FEBS Lett 1995;372:54-8.
26. Nakajima M, DeChavigny A, Johnson CE, Hamada J, Stein CA, Nicolson GL. Suramin. A potent inhibitor of melanoma heparanase and invasion. J Biol Chem 1991;266:9661-6.
27. Shinagawa S, Muroi M, Itoh T, Tobita T. Tetronic acid derivatives, its manufacturing methods and uses. Jpn Kokai Tokkyo Koho 1993;JP 05-43568: 1-26.
28. Roggo BE, Petersen F, Delmendo R, Jenny HB, Peter HH, Roesel J. 3-Alkanoyl-5-hydroxymethyl tetronic acid homologues and resistomycin: new inhibitors of HIV-1 protease. I. Fermentation, isolation and biological activity. J Antibiot (Tokyo) 1994;47:136-42.
29. Roggo BE, Hug P, Moss S, Raschdorf F, Peter HH. 3-Alkanoyl-5-hydroxymethyl tetronic acid homologues: new inhibitors of HIV-1 protease. II. Structure determination. J Antibiot (Tokyo) 1994;47:143-7.
30. Hulett MD, Hornby JR, Ohms SJ, et al. Identification of active-site residues of the pro-metastatic endoglycosidase heparanase. Biochemistry 2000;39:15659-67.
31. Ishida K, Wierzba MK, Teruya T, Simizu S, Osada H. Novel heparan sulfate mimetic compounds as antitumor agents. Chem Biol 2004;11: 367-77.
32. Sodeoka M, Sampe R, Kojima S, et al. Synthesis of a tetronic acid library focused on inhibitors of tyrosine and dual-specificity protein phosphatases and its evaluation regarding VHR and cdc25B inhibition. J Med Chem 2001;44:3216-22.
33. Mathias LJ. Esterification and alkylation reactions employing isoureas. Synthesis 1979:561-76.
34. Simizu S, Ishida K, Wierzba MK, Osada H. Secretion of heparanase protein is regulated by glycosylation in human tumor cell lines. J Biol Chem 2004;279:2697-703.
35. De Vouge MW, Yamazaki A, Bennett SA, et al. Immunoselection of GRP94/endoplasmin from a KNRK cell-specific λ gt 11 library using antibodies directed against a putative heparanase amino-terminal peptide. Int J Cancer 1994;56:286-94.
36. Ichikawa Y, Igarashi Y, Ichikawa M, Suhara Y. 1-N-iminosugars: potent and selective inhibitors of β-glycosidases. J Am Chem Soc 1998; 120:3007-18.
37. Guo W, Hiratake J, Ogawa K, Yamamoto M, Ma SJ, Sakata K. β-D-glycosylamidines: potent, selective, and easily accessible 1-glycosidase inhibitors. Bioorg Med Chem Lett 2001;11:467-70.
38. Albini A, Iwamoto Y, Kleinman HK, et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987;47: 3239-45.
39. Nakae K, Yoshimoto Y, Sawa T, et al. Migrastatin, a new inhibitor of tumor cell migration from Streptomyces sp. MK929-43F1. Taxonomy, fermentation, isolation and biological activities. J Antibiot (Tokyo) 2000; 53:1130-6.
40. Isobe I, Michikawa M, Yanagisawa K. Enhancement of MTT, a tetrazolium salt, exocytosis by amyloid β-protein and chloroquine in cultured rat astrocytes. Neurosci Lett 1999;266:129-32.
41. Zechel DL, Withers SG. Glycosidase mechanisms: anatomy of a finely tuned catalyst. Acc Chem Res 2000;33:11-8.
42. Lillelund VH, Jensen HH, Liang X, Bols M. Recent developments of transition-state analogue glycosidase inhibitors of non-natural product origin. Chem Rev 2002;102:515-53.
43. Yamaguchi T, Saito K, Tsujimoto T, Yuki H. NMR spectroscopic studies on the tautomerism in tenuazonic acid analogs. J Heterocyclic Chem 1976;13:533-7.
44. Shiozawa H, Takahashi M, Takatsu T, et al. Trachyspic acid, a new metabolite produced by Talaromyces trachyspermus, that inhibits tumor cell heparanase: taxonomy of the producing strain, fermentation, isolation, structural elucidation, and biological activity. J Antibiot (Tokyo) 1995;48: 357-62.
45. Takatsu T, Takahashi M, Kawase Y, et al. A-72363 A-1, A-2 and C, novel heparanase inhibitors from Streptomyces nobilis SANK 60192. I. Taxonomy of producing organism, fermentation, isolation and structure elucidation. J Antibiot (Tokyo) 1996;49:54-60.
46. Kawase Y, Takahashi M, Takatsu T, Arai M, Nakajima M, Tanzawa K. A-72363 A-1, A-2, and C, novel heparanase inhibitors from Streptomyces nobilis SANK 60192. II. Biological activities. J Antibiot (Tokyo) 1996;49: 61-4.
47. Nishimura Y, Shitara E, Adachi H, et al. Flexible synthesis and biological activity of uronic acid-type gem-diamine 1-N-iminosugars: a new family of glycosidase inhibitors. J Org Chem 2000;65:2-11.
48. Gingis-Velitski S, Zetser A, Flugelman MY, Vlodavsky I, Ilan N. Heparanase induces endothelial cell migration via protein kinase B/Akt activation. J Biol Chem 2004;279:23536-41.
49. Woods A, Couchman JR. Syndecan 4 heparan sulfate proteoglycan is a selectively enriched and widespread focal adhesion component. Mol Biol Cell 1994;5:183-92.
50. Wilcox-Adelman SA, Denhez F, Goetinck PF. Syndecan-4 modulates focal adhesion kinase phosphorylation. J Biol Chem 2002;277:32970-7.
51. Thodeti CK, Albrechtsen R, Grauslund M, et al. ADAM12/syndecan-4 signaling promotes β1 integrin-dependent cell spreading through protein kinase Cα and RhoA. J Biol Chem 2003;278:9576-84.
52. Vlodavsky I, Bar-Shavit R, Ishai-Michaeli R, Bashkin P, Fuks Z. Extracellular sequestration and release of fibroblast growth factor: a regulatory mechanism? Trends Biochem Sci 1991;16:268-71.